SAN DIEGO – Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), identified for supplying reagents and companies to the life science analysis and biotechnology sectors, has indicated its anticipated complete income for the fiscal 12 months 2024.
Shares fell 5% in after-hours commerce Wednesday.
The corporate’s preliminary year-end outcomes, that are topic to plain year-end changes, counsel that its income is anticipated to align with the mid-point of its beforehand forecasted vary of $255 million to $265 million.
This projection is positioned within the neighborhood of the consensus estimate, which predicts a fiscal 12 months income of roughly $260.78 million.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
Singapore, Singapore, January tenth, 2025, Chainwire Bifrost has introduced that vDOT, Polkadot‘s largest liquid staking…
Silver Lake entities have offered shares of Dell Applied sciences Inc. (NYSE:DELL) value roughly $40.3…
Digital Arts' SWOT evaluation: gaming big's inventory faces combined outlook
WASHINGTON (Reuters) - U.S. mortgage charges elevated to a contemporary six-month excessive this week, a…
LONDON (Reuters) - Wind energy supplied 20% of the electrical energy consumed in Europe final…
MILAN (Reuters) -Italy's Prada (OTC:PRDSY) is among the many potential suitors vogue group Versace which…